Comparison of the Efficacy and Safety of Duloxetine and Gabapentin in Diabetic Peripheral Neuropathic Pain: A Meta-Analysis

Table 1

The basic characteristics of the included studies.

Study	Year	Country	Study design	Medication methods/duration		Patients	Age	Baseline VAS	Outcomes
				Dul	Gab	Dul/gab	Dul/gab	Dul/gab
Majdinasab et al. [2]	2019	Iran	Double-blinded, RCT	Duloxetine, 60 mg, QD/8 weeks.	Gabapentin, 300 mg, TID/8 weeks.	52/52	59.7 ± 5.6/60.7 ± 5.7	62 ± 21.2/64 ± 20	①②④⑤
Khasbage et al. [7]	2020	India	Open-label, RCT	Duloxetine, 60 mg, QD/12 weeks.	Gabapentin, 300 mg, QD/12 weeks.	43/43	53 ± 8.4/55.9 ± 10.8	72.44 ± 8.5/73.37 ± 10.56	①
Devi et al. [9]	2012	India	Open-label, RCT	Duloxetine, 120 mg, QD/12 weeks.	Gabapentin, 1800 mg, QD/12 weeks	50/50	58.48 ± 8.8/57.22 ± 10.5	57.1 ± 16.1/60.1 ± 17.6	①②④⑤
Wang et al. [13]	2013	China	RCT	Duloxetine, 60 mg, QD/4 weeks.	Gabapentin, 3600 mg, QD/4 weeks.	32/33	56 ± 5/55 ± 5	71 ± 12/71 ± 10	①②③
Tan et al. [12]	2013	China	RCT	Duloxetine, 60 mg, QD/8 weeks.	Gabapentin, 3600 mg, QD/8 weeks.	53/47	64.2 ± 7.9/64.7 ± 10.7	70.3 ± 7.8/72.4 ± 7.5	①②
Li et al. [10]	2014	China	RCT	Duloxetine, 60 mg, QD/4 weeks.	Gabapentin, 1200 mg, TID/4 weeks.	53/53	58.4 ± 12.5/57.6 ± 12.9	71.3 ± 10.9/71.7 ± 11.3	①②③
Mei et al. [11]	2010	China	RCT	Duloxetine, 60 mg, QD/4 weeks.	Gabapentin, 3600 mg, QD/4 weeks.	31/32	65.4 ± 5.2/55.2 ± 5.4	71.2 ± 11.2/70.4 ± 9.5	①②③

Dul : duloxetine group; Gab : gabapentin group; ①: VAS pain score; ②: incidence of adverse reactions; ③: response rate; ④: sleep disturbance score; ⑤: clinical overall change impression; RCT : randomized controlled trial.